Background: Exercise and supplementation with isoflavones are therapies used to prevent and treat climacteric symptoms.
Aim: To verify the effects of 10 weeks of combined aerobic and resistance training and isoflavone supplementation on climacteric symptoms in postmenopausal women.
Methods: A randomised, double-blind, controlled clinical trial was performed. A total of 32 postmenopausal women, aged 54.4 ± 5.4 years, with a body mass index of 26.6 ± 3.0 kg/m and 5.6 ± 4.6 years after menopause, were randomly assigned to groups: placebo and exercise (PLA + EXE, n = 15) or 100 mg of isoflavone and exercise (ISO + EXE, n = 17). At the beginning and after 10 weeks of aerobic + resistance (20 min each, moderate intensity) training, climacteric symptoms were evaluated using the Blatt-Kupperman Menopausal Index, Cervantes Scale and Menopause Rating Scale. ANCOVA was used for analysis between groups and at different times, with the covariate adjusted by the pre-value. The level of significance considered was p < 0.05.
Results: A reduction in climacteric symptoms was observed in both groups, without differences between the interventions. The reductions were 45% and 50% for the Blatt-Kupperman Menopausal Index, 41% and 52% for the MRS and 39% and 39% for the Cervantes Scale in the ISO + EXE and PLA + EXE groups, respectively. In the descriptive analysis of the Blatt-Kupperman Menopausal Index values, there was an increase in the absence of symptoms from 48-77% in the ISO + EXE group and 24-58% in the PLA + EXE group.
Conclusions: A period of 10 weeks of combined training was effective in improving climacteric symptoms in post-menopausal women. However, isoflavone supplementation did not promote additional effects in improving symptoms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/0260106017727359 | DOI Listing |
Sci Rep
January 2025
Opensci, LLC, Tucson, AZ, 85750, USA.
The transition to menopause is associated with disappearance of menstrual cycle symptoms and emergence of vasomotor symptoms. Although menopausal women report a variety of additional symptoms, it remains unclear which emerge prior to menopause, which occur in predictable clusters, how clusters change across the menopausal transition, or if distinct phenotypes are present within each life stage. We present an analysis of symptoms in premenopausal to menopausal women using the MenoLife app, which includes 4789 individuals (23% premenopausal, 29% perimenopausal, 48% menopausal) and 147,501 symptom logs (19% premenopausal, 39% perimenopausal, 42% menopausal).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
The Catholic University of Korea, Seoul, Korea, Republic of (South).
Background: Women's elevated risk of Alzheimer's disease (AD) compared to men remains unclear, with gonadal hormones proposed as potential contributors. This study aimed to explore the association between follicle-stimulating hormone (FSH), estradiol (E2), neuropsychological AD stages, and cerebral Aβ deposition.
Methods: A total of 679 subjects were included in the study (N = 198 for cognitively normal (CN), N = 373 for mild cognitive impairment (MCI), and N = 108 for AD dementia groups).
Alzheimers Dement
December 2024
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Background: Women are at increased risk for Alzheimer's disease (AD) compared to men. Given research supporting up to 40% of AD cases as preventable with lifestyle modification, midlife represents a critical time of life to intervene on dementia risks; however, little research has examined women-specific presentation of risk at midlife, or how menopause staging may impact risk presentation. The aim of this study was to assess dementia risk profiles in women at risk for AD due to family history, including self-reported and lab-based modifiable risks, and to determine the role of menopause on risk presentation.
View Article and Find Full Text PDFBackground: More than 2/3 of Alzheimer's Disease (AD) patients are women, which has led to increased interest in the neurophysiological impact of estrogen decline during menopause. While early evidence suggested that hormone replacement therapy (HRT) may be protective against dementia, more recent studies have found inconclusive or even harmful effects.
Method: We tested the association between HRT use (estrogen or estrogen + progestin) and AD-related neuropathological outcomes measured on autopsy data in females from the National Alzheimer's Coordinating Center (NACC) (N = 3423).
Alzheimers Dement
December 2024
Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
Background: Menopause has been associated with greater dementia risk. We investigated the relationship between the presence of specific symptoms experienced during menopause (i.e.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!